Abstract
Aim: There are many people with type 2 Diabetes Mellitus (T2DM) worldwide. Rouxen- Y Gastric Bypass (RYGB) is an effective surgery for treating T2DM with beneficial effects on β cell metabolism. However, the mechanism of how RYGB affects the pancreas, is not clear. We focused on metabolic changes in the pancreas of rats following RYGBand to investigate complex postoperative pancreatic metabolic reprogramming and to understand how RYGB improves islet function.
Methods: We performed RYGBonstreptozotocin-induced male T2DM rats. Then we measured indicators such as weight, fasting GLU, etc. After 10 weeks, pancreatic tissues were removed to identify and quantify differentially expressed proteins. Furthermore, functional analysis of these proteins and their associated pathways was conducted by bioinformatics methods.
Results: After surgery, 451 differentially expressed proteins associated with the mechanism ofRYGB were identified. Protein levels of regenerating islet-derived protein 3 (Reg3A), cell division cycle-associated protein 2 (CDCA2), and ADP-ribosylation factor 1 (Arf1) varied greatly, and Arf1 may be a point target in diabetes.
Conclusion: This research shows that RYGB could treat T2DM through changes in the pancreatic proteins. It will give some new insight into the molecular mechanism behind the effect of RYGB.
Keywords: T2DM, RYGB, proteomics, pancreatic protein, reg3A, CDCA2, Arf1.
Graphical Abstract
Current Proteomics
Title:iTRAQ-Based Proteomic Analysis of the Rat Pancreas Following Gastric Bypass Surgery
Volume: 18 Issue: 4
Author(s): Zhuolin Xie, Lu Bai, Xiang Gao, Liyong Zhu, Shaihong Zhu, Weizheng Li*Pengzhou Li*
Affiliation:
- Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan,China
- Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan,China
Keywords: T2DM, RYGB, proteomics, pancreatic protein, reg3A, CDCA2, Arf1.
Abstract:
Aim: There are many people with type 2 Diabetes Mellitus (T2DM) worldwide. Rouxen- Y Gastric Bypass (RYGB) is an effective surgery for treating T2DM with beneficial effects on β cell metabolism. However, the mechanism of how RYGB affects the pancreas, is not clear. We focused on metabolic changes in the pancreas of rats following RYGBand to investigate complex postoperative pancreatic metabolic reprogramming and to understand how RYGB improves islet function.
Methods: We performed RYGBonstreptozotocin-induced male T2DM rats. Then we measured indicators such as weight, fasting GLU, etc. After 10 weeks, pancreatic tissues were removed to identify and quantify differentially expressed proteins. Furthermore, functional analysis of these proteins and their associated pathways was conducted by bioinformatics methods.
Results: After surgery, 451 differentially expressed proteins associated with the mechanism ofRYGB were identified. Protein levels of regenerating islet-derived protein 3 (Reg3A), cell division cycle-associated protein 2 (CDCA2), and ADP-ribosylation factor 1 (Arf1) varied greatly, and Arf1 may be a point target in diabetes.
Conclusion: This research shows that RYGB could treat T2DM through changes in the pancreatic proteins. It will give some new insight into the molecular mechanism behind the effect of RYGB.
Export Options
About this article
Cite this article as:
Xie Zhuolin, Bai Lu , Gao Xiang, Zhu Liyong , Zhu Shaihong, Li Weizheng *, Li Pengzhou *, iTRAQ-Based Proteomic Analysis of the Rat Pancreas Following Gastric Bypass Surgery, Current Proteomics 2021; 18 (4) . https://dx.doi.org/10.2174/1570164617999201116153530
DOI https://dx.doi.org/10.2174/1570164617999201116153530 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
“PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition Aliskiren: A New Drug for an Old Problem
Cardiovascular & Hematological Agents in Medicinal Chemistry L-Arginine Availability as a Pathological Mechanism in Essential Hypertension, Chronic Renal and Heart Failure
Vascular Disease Prevention (Discontinued) Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement
Current Vascular Pharmacology A Review of Oxidative Stress Related Genes and New Antioxidant Therapy in Diabetic Nephropathy
Cardiovascular & Hematological Agents in Medicinal Chemistry Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditions
Current Medicinal Chemistry Natural Compounds as Source of Aldose Reductase (AR) Inhibitors for the Treatment of Diabetic Complications: A Mini Review
Current Drug Metabolism Role of Angiotensin II in the Development of Nephropathy and Podocytopathy of Diabetes
Current Diabetes Reviews Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease
Current Pharmaceutical Design Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Drug Therapies in the Secondary Prevention of Cardiovascular Diseases:Successes, Shortcomings and Future Directions
Current Vascular Pharmacology Anti-Inflammatory Effects of C-Peptide Prevent Endothelial Dysfunction in Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ascorbic Acid and Gene Expression: Another Example of Regulation of Gene Expression by Small Molecules?
Current Genomics Cardiorenal Consequences of Atherosclerosis and Statins Therapy: From the Past to the Future
Current Pharmaceutical Design Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits
Cardiovascular & Hematological Disorders-Drug Targets Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors
Current Medicinal Chemistry The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach
Current Diabetes Reviews Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design